Legend Biotech (LEGN) Shows Strong Q3 Performance Despite Revenue Shortfall
Legend Biotech posted Q3 2025 EPS of -$0.11 and revenue of $272.33 million, supported by strong demand for CARVYKTI®.The post Legend Biotech (LEGN) Shows Strong Q3 Performance Despite Revenue Shortfall appeared first on Tokenist.